Rossari Biotech (ROSSARI) | Financial Analysis & Statements
Rossari Biotech Ltd. Small-cap Basic Materials
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
5.4B
Gross Profit
1.7B
31.70%
Operating Income
501.1M
9.22%
Net Income
336.0M
6.18%
EPS (Diluted)
₹6.06
Balance Sheet Metrics
Total Assets
19.0B
Total Liabilities
7.1B
Shareholders Equity
11.9B
Debt to Equity
0.60
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Rossari Biotech Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 20.7B | 18.3B | 16.5B | 14.8B | 7.1B |
| Cost of Goods Sold | 14.5B | 13.0B | 11.8B | 11.1B | 4.7B |
| Gross Profit | 6.2B | 5.2B | 4.7B | 3.6B | 2.4B |
| Gross Margin % | 30.0% | 28.6% | 28.6% | 24.5% | 34.3% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 1.2B | 813.3M | 828.4M | 634.8M | 431.6M |
| Other Operating Expenses | 846.5M | 693.6M | 601.9M | 395.3M | 188.3M |
| Total Operating Expenses | 2.1B | 1.5B | 1.4B | 1.0B | 619.9M |
| Operating Income | 1.9B | 1.8B | 1.5B | 1.3B | 1.0B |
| Operating Margin % | 9.0% | 10.0% | 9.2% | 8.8% | 14.2% |
| Non-Operating Items | |||||
| Interest Income | 8.6M | 22.4M | 25.2M | 40.7M | 42.6M |
| Interest Expense | 178.1M | 193.7M | 223.2M | 126.6M | 29.9M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 1.9B | 1.8B | 1.4B | 1.4B | 1.1B |
| Income Tax | 488.1M | 469.3M | 369.6M | 385.8M | 267.9M |
| Effective Tax Rate % | 26.4% | 26.4% | 25.6% | 28.3% | 25.1% |
| Net Income | 1.4B | 1.3B | 1.1B | 977.0M | 800.5M |
| Net Margin % | 6.6% | 7.2% | 6.5% | 6.6% | 11.3% |
| Key Metrics | |||||
| EBITDA | 2.7B | 2.5B | 2.3B | 2.0B | 1.3B |
| EPS (Basic) | ₹24.66 | ₹23.67 | ₹19.46 | ₹17.81 | ₹15.56 |
| EPS (Diluted) | ₹24.63 | ₹23.62 | ₹19.38 | ₹17.70 | ₹15.47 |
| Basic Shares Outstanding | 55307858 | 55209962 | 55114297 | 54848162 | 51565168 |
| Diluted Shares Outstanding | 55307858 | 55209962 | 55114297 | 54848162 | 51565168 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Rossari Biotech Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 442.0M | 251.7M | 692.0M | 374.8M | 152.1M |
| Short-term Investments | 722.6M | 416.2M | 793.0M | 269.5M | 731.5M |
| Accounts Receivable | 4.7B | 4.3B | 3.5B | 3.0B | 1.4B |
| Inventory | 3.6B | 2.8B | 1.9B | 1.9B | 953.5M |
| Other Current Assets | 8.2M | 7.4M | 6.3M | 483.3M | 242.2M |
| Total Current Assets | 10.4B | 8.4B | 7.2B | 6.1B | 3.5B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 3.1B | 3.1B | 442.0M | 69.4M |
| Goodwill | 3.6B | 3.8B | 3.9B | 3.5B | 160.1M |
| Intangible Assets | 1.3B | 1.4B | 1.6B | 1.7B | 107.6M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 30.0K | 30.0K | 30.0K | 710.0K | 1.1M |
| Total Non-Current Assets | 8.5B | 7.3B | 6.5B | 6.5B | 2.1B |
| Total Assets | 19.0B | 15.7B | 13.7B | 12.6B | 5.6B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 2.9B | 2.2B | 1.8B | 1.9B | 1.3B |
| Short-term Debt | 956.6M | 745.6M | 390.0M | 84.3M | 0 |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 894.1M | 897.7M | 940.1M | 677.8M | 68.8M |
| Total Current Liabilities | 5.4B | 4.2B | 3.5B | 2.9B | 1.5B |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.2B | 442.3M | 349.3M | 0 | 0 |
| Deferred Tax Liabilities | 465.7M | 514.7M | 587.2M | 689.5M | 12.9M |
| Other Non-Current Liabilities | - | - | 73.9M | 850.3M | - |
| Total Non-Current Liabilities | 1.7B | 996.9M | 1.0B | 1.6B | 23.9M |
| Total Liabilities | 7.1B | 5.2B | 4.5B | 4.5B | 1.5B |
| Equity | |||||
| Common Stock | 110.7M | 110.5M | 110.3M | 110.1M | 103.9M |
| Retained Earnings | 7.0B | 5.6B | 4.4B | 3.3B | 2.4B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 11.9B | 10.5B | 9.2B | 8.1B | 4.1B |
| Key Metrics | |||||
| Total Debt | 2.2B | 1.2B | 739.3M | 84.3M | 0 |
| Working Capital | 5.1B | 4.2B | 3.7B | 3.1B | 2.0B |
Balance Sheet Composition
Rossari Biotech Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 1.9B | 1.8B | 1.4B | 1.4B | 1.1B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 680.0K | 6.9M | 9.4M | 18.3M | 16.3M |
| Working Capital Changes | -1.6B | -2.1B | -278.7M | -907.1M | -724.8M |
| Operating Cash Flow | 440.1M | -114.2M | 1.4B | 550.4M | 347.2M |
| Investing Activities | |||||
| Capital Expenditures | -1.6B | -1.3B | -311.9M | -363.1M | -559.0M |
| Acquisitions | -3.2M | -177.3M | -985.3M | -3.6B | -43.4M |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | 15.5M | 137.2M |
| Investing Cash Flow | -1.6B | -1.4B | -1.3B | -3.0B | -407.1M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -27.6M | -27.6M | -27.5M | -27.5M | -25.4M |
| Debt Issuance | 934.8M | 0 | 449.2M | 0 | 0 |
| Debt Repayment | -385.8M | -115.8M | 0 | -48.1M | -610.1M |
| Financing Cash Flow | 844.5M | 329.9M | 669.6M | 2.9B | -477.5M |
| Free Cash Flow | -210.7M | -880.3M | 1.2B | -88.7M | -103.2M |
| Net Change in Cash | -303.5M | -1.2B | 728.6M | 403.2M | -537.4M |
Cash Flow Trend
Rossari Biotech Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
20.79
Forward P/E
17.98
Price to Book
2.28
Price to Sales
1.25
PEG Ratio
-2.83
Profitability Ratios
Profit Margin
6.01%
Operating Margin
8.47%
Return on Equity
11.50%
Return on Assets
7.19%
Financial Health
Current Ratio
1.94
Debt to Equity
28.18
Beta
0.33
Per Share Data
EPS (TTM)
₹24.84
Book Value per Share
₹226.03
Revenue per Share
₹413.78
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ROSSARI | 28.6B | 20.79 | 2.28 | 11.50% | 6.01% | 28.18 |
| Asian Paints | 2.4T | 62.11 | 12.16 | 18.28% | 11.10% | 17.61 |
| Pidilite Industries | 1.4T | 62.22 | 14.87 | 20.85% | 16.19% | 4.54 |
| Tanfac Industries | 49.6B | 66.26 | 14.61 | 28.25% | 10.85% | 9.28 |
| Gulf Oil Lubricants | 48.1B | 13.85 | 2.91 | 23.50% | 8.88% | 29.57 |
| Neogen Chemicals | 44.8B | 222.22 | 5.46 | 4.41% | 2.41% | 141.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.





